Ultimately, while the "Three Ones" proverb may lack scientific precision, it serves as a reminder of the close connection between nature and weather patterns. Farmers and rural communities have long relied on keen observations of the natural world to guide their agricultural practices and prepare for seasonal challenges. In a rapidly changing climate, where extreme weather events are becoming more frequent, perhaps there is wisdom in heeding the wisdom of traditional knowledge and paying attention to subtle signs in nature.Delay, deny, defend: Words on ammo in CEO shooting echo common phrase on insurer tactics
WARREN, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio ("Tevogen” or "Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN ), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today expresses gratitude to shareholders for their unwavering support and trust in Tevogen Bio and its leadership. The commitment fuels the company's determination to advance its mission of developing accessible, life-saving therapeutics. The company recently announced significant progress through its third quarter financial results for 2024, including, reduction of a net loss by $52.5 million, elimination of nearly all liabilities, and reiterating availability of sufficient capital to fund operations for the next 33 months. Ryan Saadi, MD, MPH, Founder and CEO, Tevogen Bio commented, "We remain steadfast in our mission to advance medical science, however as CEO of the company, preservation of shareholder value remains a priority. We urge all stakeholders to consider the profound impact short selling innovative healthcare companies has on lifesaving therapies. While stock price fluctuations are part of the public market dynamics, Tevogen Bio is acutely aware of the undue influence short sellers have.” William Keane, VP of Strategic Initiatives, and graduate of the FBI National Academy stated, "We are aware and monitoring the actions of potential short selling activity targeting our company. We will continue to bring light to this situation and will work with the appropriate authorities as needed.” The company plans to provide further updates on its progress in the coming weeks. About Tevogen Bio Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature's most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence. Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen's leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation. Forward-Looking Statements This press release contains certain forward-looking statements, including without limitation statements relating to: expectations regarding the healthcare and biopharmaceutical industries; Tevogen's development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases, cancer and neurological disorders, including TVGN 489 for the treatment of COVID-19 and Long COVID; Tevogen's ability to develop additional product candidates, including through use of Tevogen's ExacTcell platform; the anticipated benefits of ExacTcell; expectations regarding Tevogen's future clinical trials; and Tevogen's ability to generate revenue in the future. Forward-looking statements can sometimes be identified by words such as "may,” "could,” "would,” "expect,” "anticipate,” "possible,” "potential,” "goal,” "opportunity,” "project,” "believe,” "future,” and similar words and expressions or their opposites. These statements are based on management's expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company's control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements. Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the effect of the recent business combination with Semper Paratus Acquisition Corporation (the "Business Combination”) on Tevogen's business relationships, operating results, and business generally; the outcome of any legal proceedings that may be instituted against Tevogen; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; costs related to the Business Combination and the failure to realize anticipated benefits of the Business Combination; the failure to achieve Tevogen's commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; the ability to develop, license or acquire new therapeutics; that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the risk of regulatory lawsuits or proceedings relating to Tevogen's business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen's limited operating history; and those factors discussed or incorporated by reference in Tevogen's Annual Report on Form 10-K and subsequent filings with the SEC. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law. Contacts Tevogen Bio Communications T: 1 877 TEVOGEN, Ext 701 [email protected]
The US Department of Defense on Wednesday stepped in to bust a theory about mysterious drone spottings in New Jersey. The Pentagon denied claims that an Iran 'mothership' was responsible for launching the drones. The statement came after Rep Jeff Van Drew said he has evidence to prove that an Iranian ship putting out the drones. Deputy Defense Press Secretary Sabrina Singh said that 'no Iranian ship off the coast of the United States. There is no so-called mothership launching drones towards the United States'. The Pentagon further added that there was 'no evidence that these activities are coming from a foreign entity or the work of an adversary'. Read More: Donald Trump Is Time's 2024 'Person Of The Year', Will Celebrate At NYSE: Report Earlier in the day Congressman Van Drew, during a Fox News appearance, said: "Iran launched a mothership probably about a month ago, that contains these drones.... It's off the east coast of the United States of America. They've launched drones into everything that we can see or hear. And again, these are from high sources. I don't say this lightly." He further said that there was no 'glorified hobbyist' behind the drones, further adding that the federal government was not behind the sightings either. Read More: First Video Of Trump Tower In Jeddah Is Out - 47 Floors, 350 Apartments Planned "The third possibility was somebody, an adversarial country, doing this. Know that Iran made a deal with China to purchase drones, motherships and technology in order to go forward," said Van Drew. Earlier this week, several social media users speculated that the objects in the sky were actually UFOs. "A Ring doorbell camera captured a mysterious UFO in New Jersey on 12/8/2024. The footage shows something strange in the sky, leaving viewers puzzled. Could this be a UAP or just a trick of the light? " one person tweeted. Get Latest News Live on Times Now along with Breaking News and Top Headlines from US News, World and around the world.
The New Song Pro:Title: Premier League Matchday 16 Referee Appointment: Anthony Taylor to Officiate the Manchester DerbyIn conclusion, the release of the "Treasure Hunters" celebration artwork featuring Master Chief as Indiana Jones heralds an exciting new chapter in the Halo series. It showcases the creativity, imagination, and boldness of the developers at 343 Industries, and sets the stage for a groundbreaking gaming experience that promises to captivate and inspire fans old and new.
Dunhuang, Sanxingdui Shine on Alipay's Cultural Skin: The New Must-have for Youngsters Seeking Fortune
China's leading property developer, Country Garden, has recently found itself in hot water after being criticized by authorities for violating regulations in its property management practices. The company was issued a notice of criticism and ordered to rectify its actions. In response to the situation, Country Garden has issued a statement addressing the issue.As one of China's top property developers, Country Garden's response to the criticism will be closely monitored by industry observers and the public. The company's ability to learn from its mistakes and implement meaningful changes will ultimately determine its long-term success and reputation in the market.